Bioabsorbable stents for coronary artery disease
Canadian Coordinating Office for Health Technology Assessment
Record ID 32005000087
English, French
Authors' objectives:
To summarize the available information on the use of bioabsorbable coronary artery stents (manufactured by Guidant Corporation of Indianapolis, IN, and Igaki Medical Planning Co., Kyoto) to prevent restenosis at a blockage in the coronary arteries. Or, if a patient does not undergo angioplasty after a heart attack, these stents may be used as the initial opening device.
Authors' recommendations:
The costs of non-absorbable polymer stents and bioabsorbable stents cannot be compared because of lack of information about the latter. Results from ongoing large randomized trials will provide further efficacy and safety information, as well as a comparison of the long-term effects of this new generation of drug-eluting stents with those of current treatments.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Coronary Artery Disease
- Coronary Disease
- Coronary Restenosis
- Stents
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.